2007
DOI: 10.1245/s10434-007-9463-z
|View full text |Cite
|
Sign up to set email alerts
|

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis

Abstract: Although the HIPEC technique is feasible for patients with sarcomatosis, it is associated with significant toxicity and limited clinical benefit. Combination CDDP/MITOX failed to demonstrate any benefit over CDDP alone; moreover, there was an increase in toxicity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
41
1
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 58 publications
(45 citation statements)
references
References 48 publications
2
41
1
1
Order By: Relevance
“…35 Currently, most expert centers have stopped using this technique for this indication. [36][37][38] In the present series, intraperitoneal chemotherapy was not associated with a better outcome.…”
Section: Discussioncontrasting
confidence: 45%
“…35 Currently, most expert centers have stopped using this technique for this indication. [36][37][38] In the present series, intraperitoneal chemotherapy was not associated with a better outcome.…”
Section: Discussioncontrasting
confidence: 45%
“…Moreover, in the absence of a prognostic-based definition of sarcomatosis, it is possible that prior studies evaluating novel therapeutic strategies for the treatment of sarcomatosis have included patients with multifocal disease who may have had more favorable prognostic features, potentially contributing to the negative results reported in the majority of these trials. [25][26][27][28] An additional and perhaps even more important finding derived from this analysis is the more favorable outcome seen in patients with multifocality and less extensive disease (Յ7 tumors). Although, overall survival rates are lower as compared with patients with unifocal disease, patients in the former group had a significantly better 5-year overall survival rate as compared with those with more tumors (Ͼ7 tumors specifically) (37% vs. 7%; P 0.004).…”
Section: Discussionmentioning
confidence: 81%
“…There are few series that report the use of cytoreduction with or without intraperitoneal chemotherapy in the management of recurrent RPLPS. Most studies include multiple sarcoma histologic subtypes such as liposarcoma and gastrointestinal stromal tumor (GIST) . In a study from the Istituto Nazionale Tumori in Milan, 37 patients with sarcomatosis were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) .…”
Section: Management Of Rplps Recurrencementioning
confidence: 99%